ArticleEJNMMI research2025
Hypo-segmentation of
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPrecise modeling of boron distribution is essential for boron neutron capture therapy (BNCT) dose calculation. While full-three-dimensional (f3D) voxel modeling of ¹⁸F-BPA PET data offers high spatial resolution, its clinical value is limited by intrinsic image resolution-especially PET-and by registration errors in multi-modality image fusion. These factors constrain the reliability of voxel-level dose interpretation and increase computational burden. We propose a hypo-segmentation (hS) method that groups target tissue-to-blood ratio (TBR) values into 0.5-unit intervals to approximate boron distribution. This study retrospectively evaluated four malignant brain tumor cases, comparing dosimetric metrics derived from hS and f3D approaches. Key dose-volume parameters (D
resultsThe hS method showed strong agreement with f3D results: within 2% for tumor D
conclusionsThe hS method offers a clinically practical and computationally efficient alternative to full voxel-wise modeling. It preserves dosimetric fidelity in both tumor and normal brain regions, while aligning with the intrinsic resolution of PET and multimodal imaging. This approach supports accurate yet streamlined BNCT dose planning, particularly in clinical settings where ultra-high spatial granularity provides limited added value. TRIAL REGISTRATION NUMBER (TRN): ChiCTR2200066473, registered on December 16, 2022.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.